Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Europe Clears GSK's New Twice-Yearly Asthma Treatment

Europe Clears GSK's New Twice-Yearly Asthma Treatment

FinvizFinviz2026/02/17 11:36
By:Finviz

The European Commission on Tuesday approved GSK plc’s (NYSE:GSK) Exdensur (depemokimab) in two indications, including:

  • As an add-on maintenance treatment for severe asthma with type 2 inflammation, characterized by blood eosinophil count in adults and adolescents 12 years and older who are inadequately controlled despite high-dose inhaled corticosteroids plus another asthma controller.
  • As an add-on therapy with intranasal corticosteroids for adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery does not provide adequate disease control. 

The approval is based on data from the SWIFT and ANCHOR phase 3 trials, which showed sustained efficacy with a twice-yearly dosing regimen for depemokimab.

Trial Data

Each of the four trials met their primary or co-primary endpoints with statistically significant and clinically meaningful results, comparing the addition of depemokimab to standard of care versus standard of care alone.

Asthma affects more than 42 million people in Europe. About 5-10% of patients experience severe asthma, with many continuing to experience exacerbations and reduced quality of life despite treatment.

In addition, patients with CRSwNP face debilitating daily symptoms, and almost half remain uncontrolled.

Exdensur is a novel therapy that combines high interleukin-5 (IL-5) binding affinity and high potency with an extended half-life, enabling the sustained suppression of disease-driving type 2 inflammation with twice-yearly dosing.

In the SWIFT phase 3 trials, treatment with depemokimab resulted in a significant 58% and 48% reduction in the rate of annualised asthma exacerbations (asthma attacks) over 52 weeks from SWIFT-1 and SWIFT-2, respectively.

In a secondary endpoint from SWIFT-1 and SWIFT-2, patients treated with depemokimab experienced numerically fewer exacerbations requiring hospitalization and/or emergency department visits (1% and 4%) compared with placebo (8% and 10%), respectively.

A pre-specified pooled analysis of the two trials showed there was a 72% reduction in the annualized rate of clinically significant exacerbations requiring hospitalisation and/or ED visits over 52 weeks for depemokimab compared with placebo.

Additionally, in the ANCHOR phase 3 trials, treatment with depemokimab resulted in an improvement (reduction) from baseline in nasal polyp score (scale: 0-8) at 52 weeks and in the nasal obstruction verbal response scale over weeks 49-52.

Background

In December 2025, the U.S. Food and Drug Administration (FDA) approved Exdensur as an add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients aged 12 years and older.

Also, Exdensur recently received approval in the U.K. and Japan for the treatment of severe asthma and CRSwNP.

Price Action: GSK stock is up 2.65% at $60.49 during the premarket session at the last check on Tuesday, according to Benzinga Pro data.

Photo by JPC_PROD via Shutterstock

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Apple (AAPL.US) reportedly developing a screenless fitness band to compete with Whoop: undecided on release, earliest launch in 2028

Apple is developing a new fitness tracker to compete with Whoop.

智通财经2026/09/22 23:16

Traders Increase Hedging, Betting That the Fed's Rate Hike Cycle May Be Shallower Than Market Expectations

Traders are seeking protection against the possibility that the Federal Reserve's rate hike may be lower than the current market pricing.

智通财经2026/09/22 23:06
Traders Increase Hedging, Betting That the Fed's Rate Hike Cycle May Be Shallower Than Market Expectations

Overnight US Stock Market | Nasdaq rises for four consecutive sessions, SanDisk (SNDK.US) up 6.8%, US and Brent crude oil prices decline

At the close, the Dow Jones Industrial Average fell 185.03 points, or 0.36%, to 51,863.80 points; the S&P 500 Index gained 0.14 points, or 0.00%, to 7,764.84 points; and the Nasdaq Composite Index rose 122.18 points, or 0.45%, to 27,244.28 points.

智通财经2026/09/22 22:41

Meta (META.US) Muse sparks "AI-disrupted trading," financial, insurance, and travel stocks collectively tumble

Meta Platforms' newly launched personal AI agent Muse is sparking a new wave of "AI disruption trading" on Wall Street.

智通财经2026/09/22 22:31